INTERFERENCE WITH POSTTRANSLATIONAL MODIFICATION OF LYSINES MODIFIES STABILITY OF F508DEL CFTR

被引：0
|
作者：
Lee, S. [1 ]
Odeh, H. M. [2 ]
Matunis, M. J. [2 ]
Zeitlin, P. [1 ]
机构：
[1] Johns Hopkins Sch Med, Dept Pediat, Baltimore, MD USA
[2] Johns Hopkins Sch Publ Hlth, Dept Biochem & Mol Biol, Baltimore, MD USA
来源：
PEDIATRIC PULMONOLOGY | 2016年 / 51卷
关键词：
D O I：
暂无
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
68
引用
收藏
页码：218 / 218
页数：1
相关论文
共 50 条
  • [41] CF BONE DISEASE: EFFECT OF CFTR CORRECTORS ON HUMAN OSTEOBLASTS WITH THE F508DEL MUTATION
    Velard, F.
    Delion, M.
    Guillaume, C.
    Tabary, O.
    Barthes, F.
    Touqui, L.
    Gangloff, S.
    Sermet-Gaudelus, I
    Jacquot, J.
    PEDIATRIC PULMONOLOGY, 2014, 49 : 422 - 422
  • [42] Cystic fibrosis: scheme ELX/TEZ/IVA in children with F508del CFTR allele?
    Simon, Annika
    PNEUMOLOGIE, 2023, 77 (08):
  • [43] CFTR MODULATION WITH TEZACAFTOR/IVACAFTOR IN PATIENTS HETEROZYGOUS FOR F508DEL AND A RESIDUAL FUNCTION MUTATION
    Rowe, Steven M.
    Davies, Jane
    PEDIATRIC PULMONOLOGY, 2017, 52 : S175 - S176
  • [44] THE CHAPEROME AND CFTR MRNA ARE DOWNREGULATED IN THE NASAL TRANSCRIPTOME OF F508DEL CYSTIC FIBROSIS PATIENTS
    Sala, M.
    Reyfman, P.
    Misharin, A.
    Budingcr, G.
    Sznajder, J.
    Jain, M.
    PEDIATRIC PULMONOLOGY, 2018, 53 : 204 - 204
  • [45] Changes in LCI in F508del/F508del patients treated with lumacaftor/ivacaftor: Results from the prospect study
    Shaw, Michelle
    Khan, Umer
    Clancy, John P.
    Donaldson, Scott H.
    Sagel, Scott D.
    Rowe, Steven M.
    Ratjen, Felix
    JOURNAL OF CYSTIC FIBROSIS, 2020, 19 (06) : 931 - 933
  • [46] The solute carrier family 26 member 9 modifies rapidly progressing cystic fibrosis associated with homozygous F508del CFTR mutation
    Luo, Shiyu
    Rollins, Stuart
    Schmitz-Abe, Klaus
    Tam, Amy
    Li, Qifei
    Shi, Jiahai
    Lin, Jasmine
    Wang, Ruobing
    Agrawal, Pankaj B.
    CLINICA CHIMICA ACTA, 2024, 561
  • [47] BIOPHYSICAL MEASURES OF FULL-LENGTH CFTR THERMOSTABILITY: COMPARISON OF WILD-TYPE AND F508DEL CFTR
    Cant, N.
    Rimington, T.
    Meng, X.
    Pollock, N.
    Ford, B.
    PEDIATRIC PULMONOLOGY, 2013, 48 : 209 - 210
  • [48] Personalized Selection of a CFTR Modulator for a Patient with a Complex Allele [L467F;F508del]
    Kondratyeva, Elena
    Bulatenko, Nataliya
    Melyanovskaya, Yuliya
    Efremova, Anna
    Zhekaite, Elena
    Sherman, Viktoriya
    Voronkova, Anna
    Asherova, Irina
    Polyakov, Alexander
    Adyan, Tagui
    Kovalskaia, Valeriia
    Bukharova, Tatiana
    Goldshtein, Dmitry
    Kutsev, Sergey
    CURRENT ISSUES IN MOLECULAR BIOLOGY, 2022, 44 (10) : 5126 - 5138
  • [49] Lumacaf tor/ivacaf tor therapy fails to increase insulin secretion in F508del/F508del CF patients
    Moheet, Amir
    Beisang, Daniel
    Zhang, Lin
    Sagel, Scott D.
    VanDalfsen, Jill M.
    Heltshe, Sonya L.
    Frederick, Carla
    Mann, Michelle
    Antos, Nicholas
    Billings, Joanne
    Rowe, Steven M.
    Moran, Antoinette
    JOURNAL OF CYSTIC FIBROSIS, 2021, 20 (02) : 333 - 338
  • [50] UBIQUQITIN-SPECIFIC PROTEASE 19 STABILIZATION OF F508DEL CFTR REQUIRES ITS SUMO MODIFICATION IN AIRWAY EPTHELIAL CELLS
    Gong, X.
    Wang, X.
    Frizzell, R. A.
    PEDIATRIC PULMONOLOGY, 2020, 55 : S73 - S73
12345